<DOC>
	<DOCNO>NCT02728063</DOCNO>
	<brief_summary>The main objective study evaluate effect intestinal permeability supplementation Lactibiane Tolérance® 4 week ( 28 day ) patient suffer irritable bowel syndrome ( IBS ) diarrhea predominance . Secondary objective study evaluate effect supplementation Lactibiane Tolérance® 4 week ( 28 day ) patient suffer IBS diarrhea predominance intestinal permeability , inflammation digestive tract , symptom comfort . Single-center study single open arm : 30 volunteer adult suffer Irritable Bowel Syndrome ( IBS ) diarrhea predominance match criterion inclusion non-inclusion list .</brief_summary>
	<brief_title>Lactibiane Tolérance® Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance</brief_title>
	<detailed_description>single-center pilot study single open arm : - 2 6 week enrollment : screening visit ( visit 0 [ V0 ] ) carry verification eligibility . time V0 V1 wash-out period duration decide physician ( max 8 week ) . - The experimental phase compose 2 visit ( Visit 1 [ V1 ] Visit 2 [ V2 ] ) separate 28 day ( ± 2 day ) : V1 V2 patient take product Lactibiane Tolérance® . - V1 V2 include collection stool , blood sample , questionnaires abdominal symptom quality life , dynamic test absorption lactulose / mannitol evaluate intestinal permeability , recto-sigmoidoscopy confocal endomicroscopy in-vivo study fluorescein leakage lamina propria biopsy ex-vivo measurement . - `` carmine red '' test evaluation intestinal transit speed carry week V1 V2 ( least 72 hour visit ) . Questionnaires abdominal symptom well frequency consistency stool fill 7 day V1 V2 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Age 18 75 ; With symptom IBS predominant diarrhea accord Rome III criterion ; For woman childbearing age : effective contraception agreement keep throughout study ; General mental health compatible participation study follow outpatient opinion investigator : clinically significant relevant abnormality accord medical history physical examination ; Agreeing maintain lifestyle study ( eat habit physical activity ) ; Able willing participate research accordance protocol procedure particularly regard consumption product consideration sign informed consent form date ; Belonging social security scheme ; Willing include file volunteer participate biomedical research . Having history hypersensitivity ingredient product consideration ; Having history hypersensitivity fluorescein / red carmine ( E120 food color ) ; With immunodeficiency severe progressive disease ( cardiac , pulmonary , hepatic , renal , hematologic , neoplastic , infectious ) ; With acute severe chronic disease ( chronic alcoholism , drug addiction ) find incompatible participation study investigator ; Suffering metabolic disorder chronic inflammatory digestive disease affect intestinal transit absorption nutrient diabetes , hyperthyroidism , celiac disease Crohn 's disease ; Having medical history current condition , accord investigator , may interfere result study expose subject additional risk ; Currently medication food supplement treatment , accord investigator , may interfere result study stop within short inclusion V1 ( less month antibiotic , pre probiotic , less 14 day antidiarrheal , steroidal antiinflammatories , NSAIDs , aspirin , antihistamine drug . treatment maximum 2 concomitant psychotropic tolerate exist 3 month inclusion ) ; Having lifestyle incompatible study investigator ; Woman pregnancy breastfeed plan become pregnant within 2 month ; Planning travel hold study period impossible contact case emergency ; Having psychological linguistic inability understand sign inform consent ; Participating another clinical trial exclusion period previous clinical trial ; Having receive past 12 month , 4,500 euros payment participation clinical trial ; Under legal protection ( guardianship , trusteeship ) deprive right administrative judicial decision .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>